Health & Longevity
Novo Nordisk and Lilly Report GLP-1 Drugs Slowed Aging Clocks, but Data Are Unreviewed
Novo's 10,052-person preprint and Lilly's 71-person substudy point to slower biological aging on semaglutide and tirzepatide, yet neither has cleared peer review and weight loss may explain the effect.
·5 min read